secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cosmos Health Inc. (COSM)
CIK:        0001474167
Form:       8-K
Filed at:   2024-01-22T23:59:59+00:00
Accession:  0001477932-24-000313
Event type: m_and_a
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cosmos Health acquires 10 generic drug portfolio for $3.5M from related party
-----------------------------------------------------------------------------

- Acquired licenses/rights to 10 generic drugs from related party for €3.2M ($3.5M).
- Drugs target diabetes, cholesterol, respiratory, cardiac conditions and more.
- Manufacturing to occur at Cosmos' wholly-owned subsidiary Cana Laboratories.
- Global generic drugs market valued at $411.99B in 2022, projected to $613.34B by 2030.
- CEO says acquisition supports transition to full-fledged pharmaceutical company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1474167/000147793224000313/0001477932-24-000313-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1474167/000147793224000313/cosm_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-24-000313

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer